Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients.

Cedrés S, Ponce-Aix S, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Gómez-Abecia S, Zucchiatti AC, Sansano I, Enguita AB, Miquel JM, Viaplana C, Dienstmann R, Paz-Ares L, Felip E.

Clin Transl Oncol. 2020 Jan 8. doi: 10.1007/s12094-019-02275-9. [Epub ahead of print]

PMID:
31916017
2.

Epidermal growth factor receptor first generation tyrosine-kinase inhibitors.

Martinez-Marti A, Navarro A, Felip E.

Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S235-S246. doi: 10.21037/tlcr.2019.04.20. Review.

3.

Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient.

Domingues I, Cedres S, Callejo A, Vivancos A, Martinez-Marti A, Felip E.

Pulmonology. 2020 Jan - Feb;26(1):49-50. doi: 10.1016/j.pulmoe.2019.05.002. Epub 2019 Aug 7. No abstract available.

4.

Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLC.

Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, Kruger RG, Mohammad HP, Ballas MS, Dhar A, Govindan R.

J Thorac Oncol. 2019 Oct;14(10):1828-1838. doi: 10.1016/j.jtho.2019.06.021. Epub 2019 Jun 28.

5.

Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.

Peters S, Felip E, Dafni U, Belka C, Guckenberger M, Irigoyen A, Nadal E, Becker A, Vees H, Pless M, Martinez-Marti A, Tufman A, Lambrecht M, Andratschke N, Piguet AC, Kassapian M, Roschitzki-Voser H, Rabaglio-Poretti M, Stahel RA, Vansteenkiste J, De Ruysscher D.

Lung Cancer. 2019 Jul;133:83-87. doi: 10.1016/j.lungcan.2019.05.001. Epub 2019 May 3.

PMID:
31200833
6.

Chronic pulmonary aspergillosis in a tertiary care centre in Spain: A retrospective, observational study.

Aguilar-Company J, Martín MT, Goterris-Bonet L, Martinez-Marti A, Sampol J, Roldán E, Almirante B, Ruiz-Camps I.

Mycoses. 2019 Sep;62(9):765-772. doi: 10.1111/myc.12950. Epub 2019 Jun 25.

PMID:
31162731
7.

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O.

Ann Oncol. 2019 Aug 1;30(8):1321-1328. doi: 10.1093/annonc/mdz167.

PMID:
31125062
8.

Insight into the Role and Regulation of Gap Junction Genes in Lung Cancer and Identification of Nuclear Cx43 as a Putative Biomarker of Poor Prognosis.

Aasen T, Sansano I, Montero MÁ, Romagosa C, Temprana-Salvador J, Martínez-Marti A, Moliné T, Hernández-Losa J, Ramón y Cajal S.

Cancers (Basel). 2019 Mar 6;11(3). pii: E320. doi: 10.3390/cancers11030320.

9.

COX-2 inhibitors in NSCLC: never-ending story or misplaced?

Martinez-Marti A, Navarro A, Felip E.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S191-S194. doi: 10.21037/tlcr.2018.04.17. No abstract available.

10.

HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?

Navarro A, Martinez-Marti A, Felip E.

J Thorac Oncol. 2018 Jul;13(7):874-876. doi: 10.1016/j.jtho.2018.05.005. No abstract available.

11.

A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.

Giaccone G, Sanborn RE, Waqar SN, Martinez-Marti A, Ponce S, Zhen H, Kennealey G, Erickson-Viitanen S, Schaefer E.

Clin Lung Cancer. 2018 Sep;19(5):e567-e574. doi: 10.1016/j.cllc.2018.03.016. Epub 2018 Mar 23.

PMID:
29681434
12.

Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.

Cedrés S, Felip E, Cruz C, Martinez de Castro A, Pardo N, Navarro A, Martinez-Marti A, Remon J, Zeron-Medina J, Balmaña J, Llop-Guevara A, Miquel JM, Sansano I, Nuciforo P, Mancuso F, Serra V, Vivancos A.

J Natl Cancer Inst. 2018 Aug 1;110(8):914-917. doi: 10.1093/jnci/djy012.

13.

Corrigendum to "Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches" [Lung Cancer 106 (2017) 70-75].

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2018 Mar;117:80. doi: 10.1016/j.lungcan.2017.11.007. Epub 2018 Feb 3. No abstract available.

PMID:
29398170
14.

Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).

Martinez-Marti A, Felip E, Matito J, Mereu E, Navarro A, Cedrés S, Pardo N, Martinez de Castro A, Remon J, Miquel JM, Guillaumet-Adkins A, Nadal E, Rodriguez-Esteban G, Arqués O, Fasani R, Nuciforo P, Heyn H, Villanueva A, Palmer HG, Vivancos A.

Ann Oncol. 2017 Oct 1;28(10):2451-2457. doi: 10.1093/annonc/mdx396.

15.

Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies B2M Inactivation Impairing Immunorecognition.

Pereira C, Gimenez-Xavier P, Pros E, Pajares MJ, Moro M, Gomez A, Navarro A, Condom E, Moran S, Gomez-Lopez G, Graña O, Rubio-Camarillo M, Martinez-Martí A, Yokota J, Carretero J, Galbis JM, Nadal E, Pisano D, Sozzi G, Felip E, Montuenga LM, Roz L, Villanueva A, Sanchez-Cespedes M.

Clin Cancer Res. 2017 Jun 15;23(12):3203-3213. doi: 10.1158/1078-0432.CCR-16-1946. Epub 2017 Mar 16.

16.

Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.

Remon J, Pardo N, Martinez-Martí A, Cedrés S, Navarro A, Martinez de Castro AM, Felip E.

Lung Cancer. 2017 Apr;106:70-75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6. Review. Erratum in: Lung Cancer. 2018 Feb 1;:.

PMID:
28285697
17.

Single-cell transcriptome conservation in cryopreserved cells and tissues.

Guillaumet-Adkins A, Rodríguez-Esteban G, Mereu E, Mendez-Lago M, Jaitin DA, Villanueva A, Vidal A, Martinez-Marti A, Felip E, Vivancos A, Keren-Shaul H, Heath S, Gut M, Amit I, Gut I, Heyn H.

Genome Biol. 2017 Mar 1;18(1):45. doi: 10.1186/s13059-017-1171-9.

18.

Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.

Lung Cancer. 2016 Jun;96:1-6. doi: 10.1016/j.lungcan.2016.03.001. Epub 2016 Mar 10.

PMID:
27133741
19.

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).

Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.

PLoS One. 2015 Mar 16;10(3):e0121071. doi: 10.1371/journal.pone.0121071. eCollection 2015.

20.

Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?

Martinez P, Martinez-Marti A, Navarro A, Cedrés S, Felip E.

Lung Cancer. 2014 May;84(2):97-100. doi: 10.1016/j.lungcan.2014.01.018. Epub 2014 Jan 30. Review.

PMID:
24582269
21.

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients.

Martinez P, Hernández-Losa J, Montero MÁ, Cedrés S, Castellví J, Martinez-Marti A, Tallada N, Murtra-Garrell N, Navarro-Mendivill A, Rodriguez-Freixinos V, Canela M, Ramon y Cajal S, Felip E.

PLoS One. 2013;8(1):e52261. doi: 10.1371/journal.pone.0052261. Epub 2013 Jan 24.

22.

Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.

Felip E, Martinez-Marti A, Martinez P, Cedres S, Navarro A.

Curr Opin Oncol. 2013 Mar;25(2):115-20. doi: 10.1097/CCO.0b013e32835ca1b0. Review.

PMID:
23262832
23.

DNA repair protein expression in resected NSCLC: a different predictive value for platinum benefit in adenocarcinoma versus squamous-cell carcinoma?

Felip E, Martinez-Marti A.

Ann Oncol. 2012 Sep;23(9):2211-4. doi: 10.1093/annonc/mds157. Epub 2012 Jun 8. No abstract available.

24.

PI3K Pathway in NSCLC.

Martinez-Martí A, Felip E.

Front Oncol. 2012 Jan 6;1:55. doi: 10.3389/fonc.2011.00055. eCollection 2011.

Supplemental Content

Loading ...
Support Center